Novo Nordisk (NVO) on Tuesday announced that it is enabling select telehealth providers to offer Wegovy, expanding access to the weight loss drug as it is now in full supply. All doses of FDA-approved Wegovy are now accessible to patients of Hims & Hers Health,

Novo Nordisk collaborates with telehealth companies to expand sales and access to its weight-loss drug Wegovy, amidst efforts to curb copies. Partnering with Hims & Hers, Ro, and LifeMD, the firm aims to widen access for cash-paying patients by offering reduced prices and promoting availability despite legal challenges.